{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T18:40:09Z","timestamp":1748630409382,"version":"3.41.0"},"reference-count":7,"publisher":"Colegio Mexicano de Inmunologia Clinica y Alergia, A. C.","issue":"1","license":[{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["revistaalergia.mx"],"crossmark-restriction":false},"short-container-title":["Rev. Alergia Mex"],"abstract":"<jats:p>Background: Ixekizumab is a high-affinity IgG4 monoclonal humanized antibody useful for the treatment of ankylosing spondylitis. Benign skin reactions are a common adverse event with ixekizumab but systemic hypersensitivity reactions are much more unusual.\n\nCase report: We describe the case of a 54-female patient with HLAB27+ spondyloarthritis. Treatment with ixekizumab 80 mg subcutaneous (containing polysorbate) was prescribed. The patient experienced immediate severe dyspnea, skin erythema and flushing. Intradermal test (0.8 mg\/ml) was clearly positive in the immediate reading. The patient was planned to undergo ixekizumab desensitization according to an 8-step protocol with good tolerance.\n\nConclusion: We report a patient with HLAB27+ spondyloarthritis treated with ixekizumab who developed a systemic IgE-mediated reaction. A successful and easy to perform subcutaneous desensitization protocol is described.\n\nKeywords: Hypersensitivity; Ixekizumab; Systemic reaction; Skin test; Desensitization protocol.<\/jats:p>","DOI":"10.29262\/ram.v72i1.1424","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T16:12:40Z","timestamp":1744215160000},"page":"76-79","update-policy":"https:\/\/doi.org\/10.29262\/ram.crossmark","source":"Crossref","is-referenced-by-count":1,"title":["Successful subcutaneous desensitization in a patient with systemic reaction due to ixekizumab"],"prefix":"10.29262","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3591-1934","authenticated-orcid":false,"given":"Diego","family":"Guti\u00e9rrez Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11808","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"key":"60542","unstructured":"1. Pharmacoeconomic Review Report: Ixekizumab (Taltz): (Eli Lilly Canada Inc.): Indication: For the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to, or are intolerant to conventional therapy. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 May. PMID: 33237678."},{"key":"60543","doi-asserted-by":"crossref","unstructured":"2. Griffiths CEM, Gooderham M, Colombel JF, Terui T, et al. Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure. Dermatol Ther (Heidelb) 2022; 12 (6): 1431-1446. doi: 10.1007\/s13555-022-00743-9.","DOI":"10.1007\/s13555-022-00743-9"},{"key":"60544","doi-asserted-by":"crossref","unstructured":"3. Muraro A, Worm M, Alviani C, Cardona V, et al; European Academy of Allergy and Clinical Immunology, Food Allergy, Anaphylaxis Guidelines Group. EAACI guidelines: Anaphylaxis (2021 update). Allergy 2022; 77 (2): 357-377. doi: 10.1111\/all.15032.","DOI":"10.1111\/all.15032"},{"key":"60545","doi-asserted-by":"crossref","unstructured":"4. de la Varga-Mart\u00ednez R, Guti\u00e9rrez-Fern\u00e1ndez D, Foncubierta-Fern\u00e1ndez A, Andr\u00e9s-Garc\u00eda JA, et al. Rapid subcutaneous desensitization for treatment of hypersensitivity reactions to etanercept in two patients with positive basophil activation test. Allergol Int 2017; 66 (2): 357-359. doi: 10.1016\/j.alit.2016.09.002.","DOI":"10.1016\/j.alit.2016.09.002"},{"key":"60546","doi-asserted-by":"crossref","unstructured":"5. ALMuhizi F, De Las Vecillas-Sanchez L, Gilbert L, Copaescu AM, et al. Premedication Protocols to Prevent Hypersensitivity Reactions to Chemotherapy: a Literature Review. Clin Rev Allergy Immunol 2022; 62 (3): 534-547. doi: 10.1007\/s12016-022-08932-2.","DOI":"10.1007\/s12016-022-08932-2"},{"key":"60547","doi-asserted-by":"crossref","unstructured":"6. Jimenez RB, Vera DG, Rivera-D\u00edaz R, Cortijo-Cascajares S, et al. Successful subcutaneous desensitization in a patient with allergy to ixekizumab. J Allergy Clin Immunol Pract 2018; 6 (5): 1761-1762. doi: 10.1016\/j.jaip.2017.12.036.","DOI":"10.1016\/j.jaip.2017.12.036"},{"key":"60548","doi-asserted-by":"crossref","unstructured":"7. Bavbek S, Ataman \u015e, Ak\u0131nc\u0131 A, Castells M. Rapid subcutaneous desensitization for the management of local and systemic hypersensitivity reactions to etanercept and adalimumab in 12 patients. J Allergy Clin Immunol Pract 2015; 3 (4): 629-32. doi: 10.1016\/j.jaip.2015.01.009.","DOI":"10.1016\/j.jaip.2015.01.009"}],"container-title":["Revista Alergia M\u00e9xico"],"original-title":[],"link":[{"URL":"https:\/\/www.revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1424\/2264","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1424\/2723","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1424\/2264","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T18:13:09Z","timestamp":1748628789000},"score":1,"resource":{"primary":{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/view\/1424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,31]]},"references-count":7,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,3,31]]}},"URL":"https:\/\/doi.org\/10.29262\/ram.v72i1.1424","relation":{},"ISSN":["0002-5151","0002-5151"],"issn-type":[{"type":"print","value":"0002-5151"},{"type":"electronic","value":"0002-5151"}],"subject":[],"published":{"date-parts":[[2025,3,31]]}}}